GO
Loading...

Pharmaceuticals

More

  • Glaxo's Avandia Raises Heart Disease Risk: Study Monday, 21 May 2007 | 5:29 PM ET

    GlaxoSmithKline's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death, a new scientific analysis revealed, and the U.S. government issued a safety alert.

  • Shares of drug developers Wyeth and Elan jumped Monday after the companies said they plan on asking for approval to move their Alzheimer's treatment candidate bapineuzumab into late-stage studies.

  • Hot Stocks: Elan, Williams Among Big Movers Monday, 21 May 2007 | 1:28 PM ET

    M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.

  • 'Slingers' All Around! Friday, 18 May 2007 | 12:45 PM ET

    It sits there in front of you: a plate filled to the overflow point with chili -- and under it, two cheeseburger patties, fried potatoes and one egg, over easy.What are you about to do?

  • Contest Stocks: Acxiom Popular Winner Friday, 18 May 2007 | 12:00 PM ET

    Here's our contest stock report for both the finals and Second Chance Showdown. Acxiom proved to be a winner for several finalsts--and you can see why. It was up 18%. But those who had ADS did even better as that stock was up 24% on news of a merger. Weak earnings took a toll on the worst performing stocks--while the most active and widely held reamined the same.

  • Mad Mail Thursday, 17 May 2007 | 11:53 AM ET

    Cramer answers viewers' questions about Nutrisystem and Syneron. Plus, praise for the men and women in uniform serving in Iraq.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Looking Into ImClone's Crystal Ball Thursday, 17 May 2007 | 10:32 AM ET

    Over the past couple of days, a couple of analyst reports have come into my inbox regarding the results of the so-called "CRYSTAL" study of ImClone's Erbitux on metastatic colorectal cancer. ImClone shares Erbitux with Bristol-Myers Squibb. The drug is approved for colon and head and neck cancers, but they're testing it on other tumor types. CRYSTAL is an acronym, but you won't believe how they stretched to create it: Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer. Which came first? The acronym or the study description? Anyway, I digress. Crazy clinical trial acronyms are for another day, another blog entry.

  • Company-Changing CEOs Monday, 14 May 2007 | 8:19 PM ET

    This week Cramer is doing a series on CEOs, the best of the best when it comes to company turnarounds. These five executives have turned their once-dead franchises into living, thriving businesses. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Celeb Gold: Hello! I Had A Positive Attitude!! Monday, 14 May 2007 | 2:58 PM ET

    Comedienne and writer Judy Gold ends Trading with the Stars on a high note--with the same positive attitude she says she had throughout the contest. Good for her--and her charity, the Anti-defamation League which will receive $5,000 for Judy's participation. She did come in fifth place--but if you look at the leaderboard on the video below--that turns into first place on the second slide you'll see. So--we'll call her the first of the non winners. ( a stretch but we're trying to be as generous as Judy was with her time.)Thanks Judy--you're as good as gold!

  • Hot Stocks: Nokia, Viasys Among Big Movers Monday, 14 May 2007 | 1:06 PM ET

    M&A news and quarterly updates provided some of the catalysts behind the most actively traded stocks on Monday.

  • Supreme Court Declines Review of Amgen Patent Dispute Monday, 14 May 2007 | 12:55 PM ET

    The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.

  • German drug maker Merck announced that it is selling its generic drug business to Mylan Laboratories  for $6.6 billion.

  • A new study says if a drug is quickly developed that delays the onset of Alzheimer's Disease it would save the U.S. economy trillions of dollars.

  • Trading With Stars: Nothing To Do But Wait! Friday, 11 May 2007 | 12:54 PM ET

    Friday--today--is the last day of Trading With The Stars--and only transactions that were input by 4 pm ET Thursday will make a difference in their standings.  As the Dow fell almost 150 points, Ernie Hudson was the only celeb to show a portfolio gain Thursday--on Gmarket. Jonathan Tucker regained the top spot, and Stephen Collins fell back into second on heavy losses in Golden Telecom.  Meanwhile, Chris Moneymaker got crushed on Allscripts Healthcare, which has cost him $181,862.60 since he purchased it on 5/8, and he is now in last place. James Cromwell was hit hard by Knot Inc. which cost him $160K dropping him from 4th to 8th.

  • M&A news and analyst actions were some of the catalysts behind the most actively traded stocks on Friday.

  • ImClone Goes Hollywood Friday, 11 May 2007 | 11:05 AM ET
    Sam Waksal, former CEO of ImClone Systems

    The founder and former CEO of ImClone Systems, Sam Waksal, who is now sitting in prison for his role in the trading scandal that ensnared Martha Stewart, had a reputation for rubbing elbows with the New York glitterati and the Hollywood set. Well, it looks like ImClone is reliving its past.

  • Bristol-Myers Squibb Settles DOJ's Plavix Investigation Thursday, 10 May 2007 | 6:01 PM ET

    Bristol-Myers Squibb said it will pay up to $1 million to settle a criminal probe of a failed deal that would have delayed generic sales of blockbuster drug Plavix.

  • FDA Panel Recommends Stricter Labeling on Anemia Drugs Thursday, 10 May 2007 | 4:21 PM ET

    Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.

  • Jeff Mishlove: Response to Contest Concerns Thursday, 10 May 2007 | 1:58 PM ET

    We got an email today about guest blogger Jeff Mishlove's last stock picks--and Jeff feels he wants to address the issues raised by the emailer--that perhaps other contestants have as well. A reminder that Jeff gets no compensation for his blog posts. Here he is: A contest participant has recently raised several concerns, due to the fact that the recommendations I posted on Tuesday have done so poorly – while, simultaneously, I myself was on the leaderboard and have also benefited from sales of my Handbook for Contestants. The implicit suggestion was that, perhaps, I deliberately posted lousy stock picks at the end of this event – in order to confuse the competition and gain an edge for myself.

  • Hot Stocks: JetBlue, Vonage Among Big Movers Thursday, 10 May 2007 | 1:44 PM ET

    Analyst actions and earnings updates were some of the catalysts behind the most actively traded stocks on Thursday.